AstraZeneca plc: The ‘Sell’ That Has Been A Great ‘Buy’

Analysts who damned AstraZeneca plc (LON: AZN) as a Sell missed a great Buy. So why are brokers still calling it a Sell?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Astra’s Weak

In recent years, I seem to have read nothing but bad news about pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US). Its drugs pipeline was running dry. Innovation was in short supply. The entire business was swinging over of a patent cliff, like Michael Caine in the final scene of The Italian Job. Analysts routinely labelled it a Sell. 

So imagine my surprise when I spotted its recent share price performance figures. It is up 36% over the past two years, three times the 12% return on the FTSE 100. Over the last six months, it has grown 20%. For a stock that was apparently a screaming Sell, Astrazeneca has been a great Buy.

Sell, Sell, Sell, er, Buy

It is not difficult to see why analysts called AstraZeneca a Sell. It suffered a string of setbacks with its pipeline of antidepressant, diabetes and ovarian cancer treatments. It saw profits plummet, as key brands were open to competition from generics, and with scant signs of lucrative replacements. When investors looked forward, they saw that best-selling high cholesterol treatment drug Crestor loses protection in the US in 2016.

AstraZeneca faced troubles in every market, including government cuts in Europe, healthcare reform in the US and sluggish sales in emerging markets. Sales and revenues were plunging. Chief executive Pascal Soriot was laying off staff in their thousands in a desperate bid to turn things round. 

In retrospect, what looked like a stone Sell, was a bargain basement Buy. Because for all its problems, AstraZeneca was cheap, trading at a valuation of less than eight times earnings, while yielding almost 6%. It’s a lot more expensive today.

Piping Hot

So what went right? AstraZeneca’s decision to buy Bristol-Myers Squibb‘s interests in the two companies’ diabetes alliance has widened its exposure to the fast-growing diabetes market (550 million by 2030). At the start of this year, Soriot reported good progress in the company’s three core therapeutic areas of oncology, cardiovascular/metabolic disease, and respiratory, inflammation and autoimmune diseases. It late-stage pipeline now boasts 11 Phase-III programmes, and 27 Phase-II programmes. At long last, there were profits in the pipeline.

Soriot’s optimistic update made February’s full-year results even more disappointing. Profits were hit by loss of exclusivity on three key brands in 2013. Drug patents expiries will continue to cast a shadow this year. The dividend was frozen, as AstraZeneca directs money into researching new drugs, rather than rewarding investors. Its share buyback campaign remains in deep freeze.

Holding company

Your chance of a bargain has gone. AstraZeneca now trades at a pricier 12.7 times earnings, and yields ‘just’ 4.4%. Earnings per share are forecast to drop 17% this year. JP Morgan has just warned investors they may have to wait even longer for AstraZeneca’s $15.6 billion purchase of US firm Medimmune in 2007 to pan out. Regulatory approval for its immune-oncology medication may not come until 2017, and rivals could get there first. JPM labelled AstraZeneca a Sell. So does SocGen.

Given AstraZeneca’s pricier valuation and lower yield, I suspect the short-term gains have been made. The ‘Sell’ that was a great ‘Buy’ now looks a weak Hold at best.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey doesn't own shares in any company mentioned in this article.

More on Investing Articles

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Up 35% from this year’s low! Here’s where I think Lloyds shares are headed in H2 of 2024

My Lloyds shares are already doing well this year but that’s not guaranteed to continue. What factors could turn the…

Read more »

Investing Articles

Approaching £5, is there still growth ahead for the Rolls-Royce share price?

The Rolls-Royce share price has been flying in the last year. But is there more growth ahead or should investors…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Could Raspberry Pi be a growth share to buy and hold?

Our writer explains why he thinks a newly-listed UK growth share could have a bright future -- and considers whether…

Read more »

A pastel colored growing graph with rising rocket.
Market Movers

The FTSE 100 jumps after the Bank of England meeting. Here’s what’s next

Jon Smith runs over the takeaways from the Bank of England meeting today and flags up which FTSE 100 stocks…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

How I’d start investing in great value UK shares with £10,000 today

Harvey Jones can see a heap of UK shares he'd like to add to an ISA today. Many combine low…

Read more »